BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence